9th Circuit Eyes Pre-emption of State Law Claims Over Pharma Labeling
A federal appeals court heard oral arguments last week in a case that could carve out more guidance on whether state law claims involving labels…
October 11, 2017 at 07:49 PM
6 minute read
The original version of this story was published on The American Lawyer
Handout photo.
A federal appeals court heard oral arguments last week in a case that could carve out more guidance on whether state law claims involving labels on pharmaceuticals are pre-empted.
To argue the case on Oct. 3 before the U.S. Court of Appeals for the Ninth Circuit, both sides brought in appellate heavyweights from Washington D.C.: David Frederick of Kellogg Hansen Todd Figel & Frederick for the plaintiffs and Kannon Shanmugam of Williams & Connolly for the defendants, which include Merck Sharp & Dohme Corp. and Eli Lilly and Co.
At issue is the “clear evidence” standard that the U.S. Supreme Court set forth in its 2009 decision in Wyeth v. Levine. The high court found that federal regulatory approval of a drug didn't shield manufacturers from state law claims without “clear evidence” that the FDA would “not have approved” changes to product labels.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 2The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 3The 'Biden Effect' on Senior Attorneys: Should I Stay or Should I Go?
- 4BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 5'You Are Not Alone': 120 Sex Assault Victims Plan to Sue Sean 'Diddy' Combs
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250